Volume 13, Number 11—November 2007
Research
Human Salmonella and Concurrent Decreased Susceptibility to Quinolones and Extended-Spectrum Cephalosporins
Jean M. Whichard*
, Kathryn Gay*1, Jennifer E. Stevenson*2, Kevin J. Joyce*, Kara L. Cooper*, Michael Omondi*, Felicita Medalla*, George A. Jacoby†, and Timothy J. Barrett*
, Kathryn Gay*1, Jennifer E. Stevenson*2, Kevin J. Joyce*, Kara L. Cooper*, Michael Omondi*, Felicita Medalla*, George A. Jacoby†, and Timothy J. Barrett*Table 1
NARMS non-Typhi Salmonella serotypes with decreased susceptibility to quinolones and extended-spectrum cephalosporins, United States, 1996–2004*
| Year | No. that met MIC criteria/total tested (%) | Serotype |
||||
|---|---|---|---|---|---|---|
| Senftenberg | Typhimurium | Newport | Enteritidis | Other (no.) | ||
| 1996 | 0/1,324 (0) | |||||
| 1997 | 1/1,301 (0.08) | 1 | ||||
| 1998 | 1/1,460 (0.07) | 1 | ||||
| 1999 | 1/1,497 (0.07) | 1 | ||||
| 2000 | 4/1,377 (0.29) | 2 | 1 | 1 | ||
| 2001 | 4/1,419 (0.28) | 2 | 1 | Haifa (1) | ||
| 2002 | 5/2,008 (0.25) | 1 | 2 | 1 | Mbandaka (1) | |
| 2003 | 4/1,864 (0.21) | 2 | 1 | Agona (1) | ||
| 2004 |
7/1,793 (0.39) |
3 |
1 |
1 |
Saintpaul (1),
Uganda (1) |
|
| Total | 27/14,043 (0.19) | 11 | 6 | 3 | 2 | 5 |
*NARMS, National Antimicrobial Resistance Monitoring System. Reduced susceptibility to quinolones and extended-spectrum cephalosporins defined as MIC >32 μg/mL for nalidixic acid or >0.12 μg/mL for ciprofloxacin and >2 μg/mL for ceftiofur or >2 μg/mL for ceftriaxone.
